Literature DB >> 16640505

Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure.

Frederic Lefebvre1, Annick Préfontaine, Angelino Calderone, Alexandre Caron, Jean-François Jasmin, Louis Villeneuve, Jocelyn Dupuis.   

Abstract

Lung structural remodelling, characterized by myofibroblast proliferation and collagen deposition, contributes to impaired functional capacity in CHF (congestive heart failure). As the lung is the primary site for the formation of Ang II (angiotensin II), local modifications of this system could contribute to lung remodelling. Rats with CHF, induced following myocardial infarction (MI) via coronary artery ligation, were compared with sham-operated controls. The MI group developed lung remodelling as confirmed by morphometric measurements and immunohistochemistry. Pulmonary Ang II concentrations increased more than 6-fold (P<0.01), and AT1 (Ang II type 1) receptor expression was elevated by 3-fold (P<0.01) with evidence of distribution in myofibroblasts. AT2 (Ang II type 2) receptor expression was unchanged. In isolated lung myofibroblasts, AT1 and AT2 receptors were expressed, and Ang II stimulated proliferation as measured by [3H]thymidine incorporation. In normal rats, chronic intravenous infusion of Ang II (0.5 mg.kg(-1) of body weight.day(-1)) for 28 days significantly increased mean arterial pressure (P<0.05), without pulmonary hypertension, lung remodelling or a change in AT1 receptor expression. We conclude that there is a modification of the pulmonary renin-angiotensin system in CHF, with increased Ang II levels and AT1 receptor expression on myofibroblasts. Although this may contribute to lung remodelling, the lack of effect of increased plasma Ang II levels alone suggests the importance of local pulmonary Ang II levels combined with the effect of other factors activated in CHF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16640505     DOI: 10.1042/CS20060027

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

1.  Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.

Authors:  Yoriko Yamazato; Anderson J Ferreira; Kwon-Ho Hong; Srinivas Sriramula; Joseph Francis; Masanobu Yamazato; Lihui Yuan; Chastity N Bradford; Vinayak Shenoy; Suk P Oh; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

Review 2.  Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease.

Authors:  Jessica H Huston; Sanjiv J Shah
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

3.  Tissue-specific regulation of ACE/ACE2 and AT1/AT2 receptor gene expression by oestrogen in apolipoprotein E/oestrogen receptor-alpha knock-out mice.

Authors:  K Bridget Brosnihan; Jeffrey B Hodgin; Oliver Smithies; Nobuyo Maeda; Patricia Gallagher
Journal:  Exp Physiol       Date:  2008-01-11       Impact factor: 2.969

4.  Gene Variant of the Bradykinin B2 Receptor Influences Pulmonary Arterial Pressures in Heart Failure Patients.

Authors:  Thomas P Olson; Robert P Frantz; Stephen T Turner; Kent R Bailey; Christina M Wood; Bruce D Johnson
Journal:  Clin Med Circ Respirat Pulm Med       Date:  2009-02-17

5.  Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure.

Authors:  Andreanne Chabot; Bao Hua Jiang; Yanfen Shi; Jean-Claude Tardif; Jocelyn Dupuis
Journal:  BMC Cardiovasc Disord       Date:  2011-12-02       Impact factor: 2.298

6.  Echocardiographic validation of pulmonary hypertension due to heart failure with reduced ejection fraction in mice.

Authors:  Nour R Dayeh; Jean-Claude Tardif; Yanfen Shi; Mégane Tanguay; Jonathan Ledoux; Jocelyn Dupuis
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.